

track

Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced Chronic Kidney disease



The TRACK research study aims to determine whether a low dose of blood thinning medication will provide overall benefit and reduce heart and vascular disease for people with advanced chronic kidney disease.



Facts

Patients with advanced stages of chronic kidney disease (CKD), including those needing dialysis, have a significant burden of diseases relating to the heart and blood vessels, known as vascular disease, which shortens their life and reduces quality of life.

Over 50% of these people die due to diseases relating to heart and blood vessels.

Blood-thinning medications are used to prevent blood clots in people with heart and vascular disease, but these medications increase the risk of bleeding.

There are no blood-thinning medications that are proven to improve health in patients with kidney disease.



Risks & Benefits

A small dose of rivaroxaban, a blood thinning medication, has been proven to reduce the risk of death and major events due to heart and vascular disease (such as heart attacks, strokes and amputations), and is frequently used to help people who are at high risk of heart and vascular disease.

In people without kidney disease or with mild to moderate stages of kidney disease, the benefit of blood thinning medication is greater than the harms of these medications (such as increased bleeding).

Due to the increased dangers of both clotting of blood vessels and bleeding, treating patients with advanced stages of kidney disease with blood-thinning medications is challenging.



Evidence

Patients with advanced stages of kidney disease are largely excluded from trials testing blood-thinning medications, leading to a large evidence practice gap.

It is unknown whether blood-thinning medications, which have been shown to improve outcomes in the general population, are beneficial in patients with kidney disease.

As a result, patients with advanced stages of kidney disease miss out on life-saving medications, such as rivaroxaban.

Timeline

You will be 1 of 2000 participants in this study

Rivaroxaban OR Placebo tablet

Telephone follow-up assessment or clinic visits every 3 months

Follow-up for up to 5 years



What do I need to do?

- ✓ If you agree to take part, sign the consent form after reading it carefully. Please note participation is voluntary and your usual treatments will not be affected
- ✓ Take the medication
- ✓ There is no added cost to you & no extra tests required
- ✓ Your information will be treated strictly confidential
- ✓ Study visits will coincide with your regular clinic visits to minimise any inconvenience
- ✓ Carry a small card, which will be provided to you, at all times and show it to all health professionals you see



Yes! I am interested

Thank you for your voluntary participation to enhance our research and efforts to improve conditions for those with CKD!

If you are interested, please contact your kidney specialist for more information.

Email:

Phone: